Target group: Developing countries and countries with economies in transition.
Many individual companies are undertaking different activities in support of biosafety and research, development, transfer and use of biotechnologies in developing countries and countries with economies in transition.
An example is the Novartis biosafety programme, which has as its purpose to minimize the potential hazards in the handling of biological materials. The company has worked with research institutions in such countries as Indonesia, Philippines, Thailand and Viet Nam to develop their capacities in biotechnology, including specifically on regulatory aspects of field trials, product development and distribution. It is planning to fund a pilot biosafety programme for a selected country in Africa, to be used as a model for other countries.
An other example is Monsanto, which is working with selected research institutions in developing countries to develop biotechnology research capacity related to specific types of LMO products, with companion capacity-building activities in risk assessment and LMO regulation. This has involved work in Kenya, Mexico, Indonesia, Philippines, Thailand, Malaysia and Viet Nam.
To support research, development, transfer and use of biotechnologies in developing countries and countries with economies in transition.
To minimize the potential hazards in the hadling of biological materials.
To develop capacity-building activities in risk assessment and LMO regulation.
To develop national capacities in biotechnology, including regulatory aspects of field trials, product development and distribution.
To develop awareness and capacities for biosafety in developing countries and countries with economies in transition.